English
|
简体中文
|
繁體中文
|
한국어
|
日本語
Home
|
About us
|
Services
|
Partners
|
Events
|
Contact us
|
Login
Saturday, October 26, 2024
Press Releases for Tuesday, October 8, 2024
Awangarda-Marketing Announces Global Live Lead Generation Solutions for Finance, Real Estate, and More - New Offers until End of 2024
22:00 HKT/SGT
Lexaria Updates Current GLP-1 Market
21:20 HKT/SGT
Awangarda-Marketing Announces Global Live Lead Generation Solutions for Finance, Real Estate, and More - New Offers until End of 2024
21:00 HKT/SGT
Summit Group Urges Government of Bangladesh to Reverse Decision to Terminate FSRU Project
21:00 HKT/SGT
Innovation Beverage Group Through Sysco, the Global Leader in Foodservice Distribution, Announces Australian Bitters Now Available Nationwide in the U.S.
20:00 HKT/SGT
BlackBerry QNX Research Reveals Rising Pressure on Software Engineers Leads to Critical Trade-Offs in Safety and Security
19:58 HKT/SGT
ZeroBounce推出郵件預熱工具,提升郵件投遞率和投資回報率
19:00 HKT/SGT
ZeroBounce推出邮件预热工具,提升邮件投递率和投资回报率
19:00 HKT/SGT
ZeroBounce Launches Email Warmup Tool to Enhance Email Deliverability and ROI
19:00 HKT/SGT
Evolve Partners Alta to launch funds for Opportunities Across Private and Public Markets
16:30 HKT/SGT
三菱重工マリタイムシステムズ、鳥羽商船高等専門学校向け練習船の命名・進水式を実施
16:00 HKT/SGT
醫藥及醫療器械數字化解決方案明星升起 太美醫療科技在港上市
15:54 HKT/SGT
医药及医疗器械数字化解决方案明星升起 太美医疗科技在港上市
15:50 HKT/SGT
トヨタ、JAPAN MOBILITY SHOW BIZWEEK 2024に出展
13:30 HKT/SGT
マツダ、「JAPAN MOBILITY SHOW BIZWEEK 2024」に出展
13:00 HKT/SGT
エーザイ、痛風・高尿酸血症治療剤「URECE(R) Tablets」(一般名:ドチヌラド)についてタイで承認を取得
13:00 HKT/SGT
"Urece Tablets" (Dotinurad) Approved In Thailand For Gout And Hyperuricemia
13:00 HKT/SGT
JCB and Nuvei expand global partnership in APAC
11:00 HKT/SGT
Call for Entries Opens as MotorTrend and BlackBerry QNX Announce Third Annual Software-Defined Vehicle Innovator Awards
09:00 HKT/SGT
ACN Search:
Andy Pitre, EVP of Product, HubSpot, launching Breeze at INBOUND 2024
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home
|
About us
|
Services
|
Partners
|
Events
|
Login
|
Contact us
|
Cookies Policy
|
Privacy Policy
|
Disclaimer
|
Terms of Use
|
RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575